Literature DB >> 29487413

Patterns and predictors of repeat fecal immunochemical and occult blood test screening in four large health care systems in the United States.

Amit G Singal1, Douglas A Corley2, Aruna Kamineni3, Michael Garcia4, Yingye Zheng4, Paul V Doria-Rose5, Virginia P Quinn6, Christopher D Jensen2, Jessica Chubak3, Jasmin Tiro7, Chyke A Doubeni8, Nirupa R Ghai6, Celette Sugg Skinner7, Karen Wernli3, Ethan A Halm7.   

Abstract

OBJECTIVES: Effectiveness of fecal occult blood test (FOBT) for colorectal cancer (CRC) screening depends on annual testing, but little is known about patterns of repeat stool-based screening within different settings. Our study's objective was to characterize screening patterns and identify factors associated with repeat screening among patients who completed an index guaiac FOBT (gFOBT) or fecal immunochemical test (FIT).
METHODS: We performed a multi-center retrospective cohort study among people who completed a FOBT between January 2010 and December 2011 to characterize repeat screening patterns over the subsequent 3 years. We studied at 4 large health care delivery systems in the United States. Logistic regression analyses were used to identify factors associated with repeat screening patterns. We included individuals aged 50-71 years who completed an index FOBT and had at least 3 years of follow-up. We excluded people with a history of CRC, colonoscopy within 10 years or flexible sigmoidoscopy within 5 years before the index test, or positive index stool test. Consistent screening was defined as repeat FOBT within every 15 months and inconsistent screening as repeat testing at least once during follow-up but less than consistent screening.
RESULTS: Among 959,857 eligible patients who completed an index FIT or gFOBT, 344,103 had three years of follow-up and met inclusion criteria. Of these, 46.6% had consistent screening, 43.4% inconsistent screening, and 10% had no repeat screening during follow-up. Screening patterns varied substantially across healthcare systems, with consistent screening proportions ranging from 1 to 54.3% and no repeat screening proportions ranging from 6.9 to 42.8%. Higher consistent screening proportions were observed in health systems with screening outreach and in-reach programs, whereas the safety-net health system, which uses opportunistic clinic-based screening, had the lowest consistent screening. Consistent screening increased with older age but was less common among racial/ethnic minorities and patients with more comorbidities.
CONCLUSIONS: Adherence with annual FOBT screening is highly variable across healthcare delivery systems. Settings with more organized screening programs performed better than those with opportunistic screening, but evidence-based interventions are needed to improve CRC screening adherence in all settings.

Entities:  

Mesh:

Year:  2018        PMID: 29487413      PMCID: PMC6476786          DOI: 10.1038/s41395-018-0023-x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  28 in total

1.  Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement.

Authors: 
Journal:  Ann Intern Med       Date:  2008-10-06       Impact factor: 25.391

2.  High rate of advanced adenoma detection in 4 rounds of colorectal cancer screening with the fecal immunochemical test.

Authors:  Sergio Crotta; Nereo Segnan; Simona Paganin; Bruna Dagnes; Roberto Rosset; Carlo Senore
Journal:  Clin Gastroenterol Hepatol       Date:  2012-03-15       Impact factor: 11.382

3.  Reasons for Lack of Diagnostic Colonoscopy After Positive Result on Fecal Immunochemical Test in a Safety-Net Health System.

Authors:  Jason Martin; Ethan A Halm; Jasmin A Tiro; Zahra Merchant; Bijal A Balasubramanian; Katharine McCallister; Joanne M Sanders; Chul Ahn; Wendy Pechero Bishop; Amit G Singal
Journal:  Am J Med       Date:  2016-08-31       Impact factor: 4.965

4.  Longitudinal adherence with fecal occult blood test screening in community practice.

Authors:  Joshua J Fenton; Joann G Elmore; Diana S M Buist; Robert J Reid; Daniel J Tancredi; Laura-Mae Baldwin
Journal:  Ann Fam Med       Date:  2010 Sep-Oct       Impact factor: 5.166

5.  Randomised study of screening for colorectal cancer with faecal-occult-blood test.

Authors:  O Kronborg; C Fenger; J Olsen; O D Jørgensen; O Søndergaard
Journal:  Lancet       Date:  1996-11-30       Impact factor: 79.321

6.  Cancer statistics for African Americans, 2013.

Authors:  Carol DeSantis; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2013-02-05       Impact factor: 508.702

7.  Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.

Authors:  Leo G van Rossum; Anne F van Rijn; Robert J Laheij; Martijn G van Oijen; Paul Fockens; Han H van Krieken; Andre L Verbeek; Jan B Jansen; Evelien Dekker
Journal:  Gastroenterology       Date:  2008-03-25       Impact factor: 22.682

8.  Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force.

Authors:  Ann G Zauber; Iris Lansdorp-Vogelaar; Amy B Knudsen; Janneke Wilschut; Marjolein van Ballegooijen; Karen M Kuntz
Journal:  Ann Intern Med       Date:  2008-10-06       Impact factor: 25.391

9.  The colorectal cancer screening process in community settings: a conceptual model for the population-based research optimizing screening through personalized regimens consortium.

Authors:  Jasmin A Tiro; Aruna Kamineni; Theodore R Levin; Yingye Zheng; Joanne S Schottinger; Carolyn M Rutter; Douglas A Corley; Celette S Skinner; Jessica Chubak; Chyke A Doubeni; Ethan A Halm; Samir Gupta; Karen J Wernli; Carrie Klabunde
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-06-10       Impact factor: 4.254

10.  Cancer screening test use - United States, 2013.

Authors:  Susan A Sabatino; Mary C White; Trevor D Thompson; Carrie N Klabunde
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2015-05-08       Impact factor: 17.586

View more
  9 in total

1.  Urinary Metabolomics to Identify a Unique Biomarker Panel for Detecting Colorectal Cancer: A Multicenter Study.

Authors:  Lu Deng; Kathleen Ismond; Zhengjun Liu; Jeremy Constable; Haili Wang; Olusegun I Alatise; Martin R Weiser; T P Kingham; David Chang
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-05-31       Impact factor: 4.254

2.  Primary Care Provider Beliefs and Recommendations About Colorectal Cancer Screening in Four Healthcare Systems.

Authors:  Nirupa R Ghai; Christopher D Jensen; Sophie A Merchant; Joanne E Schottinger; Jeffrey K Lee; Jessica Chubak; Aruna Kamineni; Ethan A Halm; Celette Sugg Skinner; Jennifer S Haas; Beverly B Green; Nancy T Cannizzaro; Jennifer L Schneider; Douglas A Corley
Journal:  Cancer Prev Res (Phila)       Date:  2020-07-15

3.  A Systematic Review of Repeat Fecal Occult Blood Tests for Colorectal Cancer Screening.

Authors:  Caitlin C Murphy; Ahana Sen; Bianca Watson; Samir Gupta; Helen Mayo; Amit G Singal
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-11-18       Impact factor: 4.254

4.  Challenges and Approaches to Measuring Repeat Fecal Immunochemical Test for Colorectal Cancer Screening.

Authors:  Caitlin C Murphy; Ethan A Halm; Celette Sugg Skinner; Bijal A Balasubramanian; Amit G Singal
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-05-26       Impact factor: 4.254

5.  Making FIT Count: Maximizing Appropriate Use of the Fecal Immunochemical Test for Colorectal Cancer Screening Programs.

Authors:  Vivy T Cusumano; Folasade P May
Journal:  J Gen Intern Med       Date:  2020-03-03       Impact factor: 5.128

6.  Factors Affecting Adherence in a Pragmatic Trial of Annual Fecal Immunochemical Testing for Colorectal Cancer.

Authors:  Carrie M Nielson; William M Vollmer; Amanda F Petrik; Erin M Keast; Beverly B Green; Gloria D Coronado
Journal:  J Gen Intern Med       Date:  2019-01-25       Impact factor: 5.128

7.  Influence of Varying Quantitative Fecal Immunochemical Test Positivity Thresholds on Colorectal Cancer Detection: A Community-Based Cohort Study.

Authors:  Kevin Selby; Christopher D Jensen; Jeffrey K Lee; Chyke A Doubeni; Joanne E Schottinger; Wei K Zhao; Jessica Chubak; Ethan Halm; Nirupa R Ghai; Richard Contreras; Celette Skinner; Aruna Kamineni; Theodore R Levin; Douglas A Corley
Journal:  Ann Intern Med       Date:  2018-09-18       Impact factor: 25.391

8.  Mailed fecal immunochemical test outreach for colorectal cancer screening: Summary of a Centers for Disease Control and Prevention-sponsored Summit.

Authors:  Samir Gupta; Gloria D Coronado; Keith Argenbright; Alison T Brenner; Sheila F Castañeda; Jason A Dominitz; Beverly Green; Rachel B Issaka; Theodore R Levin; Daniel S Reuland; Lisa C Richardson; Douglas J Robertson; Amit G Singal; Michael Pignone
Journal:  CA Cancer J Clin       Date:  2020-06-25       Impact factor: 286.130

Review 9.  Framework and Strategies to Eliminate Disparities in Colorectal Cancer Screening Outcomes.

Authors:  Chyke A Doubeni; Kevin Selby; Samir Gupta
Journal:  Annu Rev Med       Date:  2020-11-18       Impact factor: 13.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.